Human LILRB2(Leukocyte Immunoglobulin Like Receptor Subfamily B Member 2) ELISA Kit

The HUMAN LILRB2 (Leukocyte Immunoglobulin Like Receptor Subfamily B Member 2) ELISA Kit is a cutting-edge diagnostic tool designed for the accurate and efficient detection of LILRB2 protein levels in human samples. This ELISA kit utilizes a highly specific and sensitive enzyme-linked immunosorbent assay technique, enabling researchers and clinicians to quantitatively measure the concentration of LILRB2 in various biological samples, including serum, plasma, and cell lysates. With its exceptional precision and reliability, this kit offers a valuable resource for studying the role of LILRB2 in immune responses and its potential implications in various diseases.

The HUMAN LILRB2 ELISA Kit features a comprehensive and user-friendly protocol, ensuring ease of use and reproducibility. The kit includes all the necessary components, including pre-coated microplate wells, standards, controls, and detection reagents, allowing for a streamlined and efficient workflow. The assay is performed by adding the sample to the microplate wells, followed by the addition of the detection reagents. After a series of washing steps, a substrate solution is added, resulting in a colorimetric reaction that is proportional to the amount of LILRB2 present in the sample. The absorbance is then measured using a microplate reader, and the concentration of LILRB2 is determined by comparing the absorbance values to a standard curve.

With its high sensitivity and wide dynamic range, the HUMAN LILRB2 ELISA Kit offers exceptional accuracy and precision in quantifying LILRB2 protein levels. This kit provides researchers and clinicians with a valuable tool for investigating the role of LILRB2 in immune regulation, inflammation, and various diseases, including cancer, autoimmune disorders, and infectious diseases. By enabling the quantitative measurement of LILRB2, this ELISA kit opens up new avenues for understanding the molecular mechanisms underlying immune responses and developing targeted therapies.